Unique ID issued by UMIN | UMIN000010000 |
---|---|
Receipt number | R000011387 |
Scientific Title | Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma. |
Date of disclosure of the study information | 2013/02/08 |
Last modified on | 2015/03/02 19:58:20 |
Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Japan |
hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
YES
To investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Safety,Efficacy
Exploratory
Explanatory
Not applicable
The clinicopathological factors related to time to progression of unresectable advanced hepatocellular carcinoma.patients treated with sorafenib.
The clinicopathological factors related to overall survival of unresectable advanced hepatocellular carcinoma patients treated with sorafenib.
The clinicopathological factors to predict serious adverse effects caused by sorafenib.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Patients with unresectable advanced hepatocellular carcinoma who are to be treated with sorafenib and from whom written informed consent was obtained.
Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 and pretreatment Child-Pugh score of 8 or more.
150
1st name | |
Middle name | |
Last name | Namiki Izumi |
Musashino Red Cross Hospital
Division of Gastroenterology and Hepatology
1-26-1, Kyonancho, Musashino, Tokyo
0422-32-3111
1st name | |
Middle name | |
Last name | Yukio Osaki |
Osaka Red Cross Hospital
department of Gatroenterology and Hepatology
5-30, Fudegasaki-cho, Tennoji-ku, Osaka
06-6774-5111
Japanese Red Cross Liver Study Group
Ministry of Health, Labour and Welfare
Division of Genome biology, Kinki University
NO
武蔵野赤十字病院, 大阪赤十字病院, その他全国赤十字病院
2013 | Year | 02 | Month | 08 | Day |
Partially published
Main results already published
2012 | Year | 05 | Month | 15 | Day |
2012 | Year | 06 | Month | 22 | Day |
2013 | Year | 10 | Month | 31 | Day |
2013 | Year | 12 | Month | 31 | Day |
2014 | Year | 01 | Month | 15 | Day |
2014 | Year | 03 | Month | 31 | Day |
To investigate the predictive factors on the efficacy of sorafenib therapy for unresectable advanced hepatocellular carcinoma.
To perform genomic analyses on patients` tumor tissue obtained by liver biopsy before sorafenib administration, and to investigate biomarkers related with clinical course including OS, PFS and adverse effects.
2013 | Year | 02 | Month | 08 | Day |
2015 | Year | 03 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011387
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |